These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
270 related articles for article (PubMed ID: 30559168)
1. Dopamine Receptor D5 is a Modulator of Tumor Response to Dopamine Receptor D2 Antagonism. Prabhu VV; Madhukar NS; Gilvary C; Kline CLB; Oster S; El-Deiry WS; Elemento O; Doherty F; VanEngelenburg A; Durrant J; Tarapore RS; Deacon S; Charter N; Jung J; Park DM; Gilbert MR; Rusert J; Wechsler-Reya R; Arrillaga-Romany I; Batchelor TT; Wen PY; Oster W; Allen JE Clin Cancer Res; 2019 Apr; 25(7):2305-2313. PubMed ID: 30559168 [TBL] [Abstract][Full Text] [Related]
2. Role of Dopamine Receptors in the Anticancer Activity of ONC201. Kline CLB; Ralff MD; Lulla AR; Wagner JM; Abbosh PH; Dicker DT; Allen JE; El-Deiry WS Neoplasia; 2018 Jan; 20(1):80-91. PubMed ID: 29216597 [TBL] [Abstract][Full Text] [Related]
3. Biological activity of weekly ONC201 in adult recurrent glioblastoma patients. Arrillaga-Romany I; Odia Y; Prabhu VV; Tarapore RS; Merdinger K; Stogniew M; Oster W; Allen JE; Mehta M; Batchelor TT; Wen PY Neuro Oncol; 2020 Jan; 22(1):94-102. PubMed ID: 31702782 [TBL] [Abstract][Full Text] [Related]
4. Pharmacological Characterization of the Imipridone Anticancer Drug ONC201 Reveals a Negative Allosteric Mechanism of Action at the D Free RB; Cuoco CA; Xie B; Namkung Y; Prabhu VV; Willette BKA; Day MM; Sanchez-Soto M; Lane JR; Laporte SA; Shi L; Allen JE; Sibley DR Mol Pharmacol; 2021 Oct; 100(4):372-387. PubMed ID: 34353882 [TBL] [Abstract][Full Text] [Related]
5. Metabolic and inflammatory reprogramming of macrophages by ONC201 translates in a pro-inflammatory environment even in presence of glioblastoma cells. Geiß C; Witzler C; Poschet G; Ruf W; Régnier-Vigouroux A Eur J Immunol; 2021 May; 51(5):1246-1261. PubMed ID: 33442873 [TBL] [Abstract][Full Text] [Related]
6. ONC201 induces the unfolded protein response (UPR) in high- and low-grade ovarian carcinoma cell lines and leads to cell death regardless of platinum sensitivity. Rumman M; Buck S; Polin L; Dzinic S; Boerner J; Winer IS Cancer Med; 2021 May; 10(10):3373-3387. PubMed ID: 33932119 [TBL] [Abstract][Full Text] [Related]
8. Selective DRD2 antagonist and ClpP agonist ONC201 in a recurrent non-midline H3 K27M-mutant glioma cohort. Odia Y; Hall MD; Cloughesy TF; Wen PY; Arrillaga-Romany I; Daghistani D; Mehta MP; Tarapore RS; Ramage SC; Allen JE Neuro Oncol; 2024 May; 26(Supplement_2):S165-S172. PubMed ID: 38386699 [TBL] [Abstract][Full Text] [Related]
9. Epidermal growth factor receptor as a molecular determinant of glioblastoma response to dopamine receptor D2 inhibitors. He Y; Li J; Koga T; Ma J; Dhawan S; Suzuki Y; Furnari F; Prabhu VV; Allen JE; Chen CC Neuro Oncol; 2021 Mar; 23(3):400-411. PubMed ID: 32830856 [TBL] [Abstract][Full Text] [Related]
10. EZH2i EPZ-6438 and HDACi vorinostat synergize with ONC201/TIC10 to activate integrated stress response, DR5, reduce H3K27 methylation, ClpX and promote apoptosis of multiple tumor types including DIPG. Zhang Y; Zhou L; Safran H; Borsuk R; Lulla R; Tapinos N; Seyhan AA; El-Deiry WS Neoplasia; 2021 Aug; 23(8):792-810. PubMed ID: 34246076 [TBL] [Abstract][Full Text] [Related]
11. [Role of dopamine receptor subtypes DRD2 and DRD5 in drug therapy of pituitary tumors]. Liu YT; Zhang Y; Wang Y; Wu ZB Zhonghua Yi Xue Za Zhi; 2019 Jun; 99(22):1703-1706. PubMed ID: 31216815 [No Abstract] [Full Text] [Related]
13. Targeting dopamine receptor D2 as a novel therapeutic strategy in endometrial cancer. Pierce SR; Fang Z; Yin Y; West L; Asher M; Hao T; Zhang X; Tucker K; Staley A; Fan Y; Sun W; Moore DT; Xu C; Tsai YH; Parker J; Prabhu VV; Allen JE; Lee D; Zhou C; Bae-Jump V J Exp Clin Cancer Res; 2021 Feb; 40(1):61. PubMed ID: 33557912 [TBL] [Abstract][Full Text] [Related]
14. Effects of the DRD2/3 antagonist ONC201 and radiation in glioblastoma. He L; Bhat K; Ioannidis A; Zhang L; Nguyen NT; Allen JE; Nghiemphu PL; Cloughesy TF; Liau LM; Kornblum HI; Pajonk F Radiother Oncol; 2021 Aug; 161():140-147. PubMed ID: 34097975 [TBL] [Abstract][Full Text] [Related]
15. Dopamine receptor D2 regulates glioblastoma survival and death through MET and death receptor 4/5. Jeon HM; Oh YT; Shin YJ; Chang N; Kim D; Woo D; Yeup Y; Joo KM; Jo H; Yang H; Lee JK; Kang W; Sa J; Lee WJ; Hale J; Lathia JD; Purow B; Park MJ; Park JB; Nam DH; Lee J Neoplasia; 2023 May; 39():100894. PubMed ID: 36972629 [TBL] [Abstract][Full Text] [Related]
16. Cancer stem cell-related gene expression as a potential biomarker of response for first-in-class imipridone ONC201 in solid tumors. Prabhu VV; Lulla AR; Madhukar NS; Ralff MD; Zhao D; Kline CLB; Van den Heuvel APJ; Lev A; Garnett MJ; McDermott U; Benes CH; Batchelor TT; Chi AS; Elemento O; Allen JE; El-Deiry WS PLoS One; 2017; 12(8):e0180541. PubMed ID: 28767654 [TBL] [Abstract][Full Text] [Related]